Pharma bets a little-known cholesterol will underpin its next blockbuster heart drugs

Novartis, Amgen and Eli Lilly are among the pharmaceutical companies developing drugs to lower levels of a particularly bad form of cholesterol called Lp(a) and potentially prevent heart attacks. Lp(a) levels are almost entirely genetically determined, making them a prime target for drugmakers.